ABOUT THE EVENT
Date: Monday, September 28, 2026 11am–12:30pm EDT
Event Location: Virtual
Behind today’s rapidly expanding clinical pipelines, CMC has emerged as one of the most critical factors determining whether an ADC can successfully reach the market. Recent FDA setbacks involving Chinese ADC assets have drawn significant industry attention, highlighting that CMC is no longer simply a back-office function, but a strategic priority that can influence company valuations, BD deal terms and long-term global competitiveness.
Against this backdrop, China BioPioneers · International Edition returns with the topic: The ADC Commercialization Era, co-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBio. This panel brings together biotech executives and industry leaders from around the world to examine how CMC and manufacturing strategy influence an ADC’s path to commercial supply and global markets—covering manufacturing models, global regulatory compliance, supply-chain resilience and long-term competitiveness.
What We Will Cover
- CMC – The Invisible Arbiter of ADC Commercialization
- The Crossroads of Manufacturing Strategy – In-House, CDMO, or Hybrid?
- Global CMC Compliance – Navigating Regulatory Expectations Across Markets
- Supply Chain Resilience – From Cost Efficiency to Strategic Security
- Looking Ahead – How CMC Will Shape the Next Generation of ADC Leaders
Moderator
• Qi Fei, MD, Legend Capital
Panelists
• Hui Feng, Founder & CEO, Allink Biotherapeutics
• George Procopiou, Vice President of ADC Chemistry and Engineering, Valink Therapeutics
• Tiejun Li, Head of CMC, AsymBio
• Ray Sison, Managing Partner & Co-founder, SCxCMC Solutions
